Lauren Massaro

Check out a recap of important pharmacy news you might have missed this week, dispensed in small doses.

The approval of xanomeline and trospium chloride (Cobenfy) from Bristol Myers Squibb represents a “transformative moment in the treatment of schizophrenia.”

In the TEMPO-1 trial, both tavapadon doses effectively reduced motor symptoms in patients with early-stage Parkinson's disease.

Study findings raise concern about increased pain and disability, poorer pain self-management, and impaired quality of life during adolescence that can continue into young adulthood.

Higher doses of buprenorphine may also be more effective against the increasing prevalence of fentanyl in the opioid crisis.

“Pharmacies are processing prescriptions, our supply chain is fully operational, and most importantly, the first patients are now receiving neffy,” said Eric Karas, CCO of ARS Pharmaceuticals.

Initiatives such as media campaigns and legislative rulings by the agencies have likely contributed to the decline.

In case you missed it, this week we had news about end-of-year PBM reform on the horizons, cebranopadol as a transformational new pain therapy, success in co-administration of RSV and shingles vaccines, and more.

Check out a recap of important pharmacy news you might have missed this week, dispensed in small doses.

Stephanie Sober, MD, MSHP, shares insights into the research that led to Opill’s FDA approval and its implications for women’s access to contraception.

“By encouraging active self-management using health coaching principles, the WalkBack intervention might be able to reduce the prevalence of recurrent low back pain and associated burden on health care systems,” wrote investigators.

A co-administration option for both vaccinations can increase the likelihood of older adults completing the vaccination series and improve health outcomes for the patient population.

Mark Garofoli combined personal anecdotes with professional expertise to deliver a compelling presentation on kidney stone pain at this year’s PAINWeek National Conference.

Lebrikizumab-lbks is a targeted treatment that addresses the root cause of atopic dermatitis; by reducing inflammation throughout the body, it can help alleviate the dry, itchy, and irritated skin that often characterizes the condition.

In case you missed it, this week we had news about novel treatments for dry eye disease, art therapy and mental health, abdominal fat's role in pain, and more.

Check out a recap of important pharmacy news you might have missed this week, dispensed in small doses.

Over 30 million American adults experience some hearing loss, yet only one-fifth benefit from hearing aids; the FDA’s approval will expand access to the technology for the patient population.

Findings could inform future clinical practices on the treatment of DED for the more than 400 million people worldwide with the condition.

Two phase 3 trials demonstrated that once-weekly insulin efsitora is as effective as daily insulin in lowering HbA1c in both type 1 (T1D) and type 2 diabetes (T2D).

“Reducing abdominal adiposity may be considered a target for chronic pain management, particularly in those with pain in multiple sites and widespread pain,” wrote investigators.

Whereby gastroparesis can hinder the absorption of oral medications in the stomach, Tonix Pharmaceuticals is promoting alternative migraine treatments that bypass the digestive system.

In case you missed it, this week we had news about digital therapeutics for anxiety, "lifeguard pharmacy" services, NCPA-backed calls to action for PBM reform, and more.

Check out a recap of important pharmacy news you might have missed this week, dispensed in small doses.

Lingo offers users a real-time glucose graph, a metric to track glucose spikes, food and activity logging, personal recommendations, and challenges to motivate healthy behaviors.

Findings were presented at the American Heart Association's Hypertension Scientific Sessions in Chicago, Illinois.

Embecta’s new patch pump offers a larger insulin reservoir to better accommodate for the needs of patients with type 2 diabetes (T2D).

Results from HERCULES will form the basis for future discussions with global regulatory authorities, according to Sanofi.

In case you missed it, this week we had news about COVID-19 and the upcoming respiratory virus season, advancements in clinical trials for ASCVD, the first OTC birth control, and more.

Check out a recap of important pharmacy news you might have missed this week, dispensed in small doses.

Emergent BioSolutions has announced that it will donate 50,000 doses of ACAM2000 for potential deployment across affected areas in Central Africa.